Concepedia

Douglas G. Johns

DG

Statistics

Publications

73

Citations

3.7K

H-Index

32

Active since

1976

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

GlaxoSmithKline (United States)

GlaxoSmithKline (United Kingdom)

University of Michigan

UNSW Sydney

Douglas G. Johns is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in life sciences, pharmacology, and biochemistry.

ORCID

Publications per year

1976–2023

73

Publications

73

Role of NADPH Oxidase in the Vascular Hypertrophic and Oxidative Stress Response to Angiotensin II in Mice

Hui Di Wang, Shanqin Xu, Douglas G. Johns et al. · Circulation Research · 2001 · 343 citations · Full text

, , +17

Discovery of GSK2795039, a Novel Small Molecule NADPH Oxidase 2 Inhibitor

Kazufumi Hirano, Woei Shin Chen, Adeline L.W. Chueng et al. · Antioxidants and Redox Signaling · 2015 · 197 citations · Full text

, , +14

Monocyte tissue factor–dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin

A. Phillip Owens, Freda Passam, Silvio Antoniak et al. · Journal of Clinical Investigation · 2012 · 168 citations

, , +17

A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors

Thomas J. Tucker, Mark W. Embrey, Candice Alleyne et al. · Journal of Medicinal Chemistry · 2021 · 152 citations · Full text

, , +17

Lysophosphatidylcholine induces inflammatory activation of human coronary artery smooth muscle cells

Nambi Aiyar, Jyoti Disa, Zhaohui Ao et al. · Molecular and Cellular Biochemistry · 2006 · 142 citations

, , +12

1–5 of 73